Zhongzhi Pharmaceutical Holdings Valuation

Is 3737 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 3737 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 3737's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 3737's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 3737?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 3737. This is calculated by dividing 3737's market cap by their current preferred multiple.
What is 3737's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	CN¥706.81m

3737 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.3x
Enterprise Value/EBITDA	4.6x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 3737's PE Ratio compare to its peers?

The above table shows the PE ratio for 3737 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	7.2x
8049 Jilin Province Huinan Changlong Bio-pharmacy	4.2x	n/a	HK$795.6m
503 Lansen Pharmaceutical Holdings	13x	n/a	HK$750.6m
2161 JBM (Healthcare)	5.6x	n/a	HK$729.0m
2633 Jacobson Pharma	6.2x	n/a	HK$1.1b
3737 Zhongzhi Pharmaceutical Holdings	6.3x	n/a	HK$777.2m

Price-To-Earnings vs Peers: 3737 is good value based on its Price-To-Earnings Ratio (6.3x) compared to the peer average (7.2x).

Price to Earnings Ratio vs Industry

How does 3737's PE Ratio compare vs other companies in the HK Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	8.1%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	8.1%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: 3737 is good value based on its Price-To-Earnings Ratio (6.3x) compared to the Hong Kong Pharmaceuticals industry average (7.9x).

Price to Earnings Ratio vs Fair Ratio

What is 3737's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

3737 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	6.3x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 3737's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.